Relmada Therapeutics, Inc.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On May 28, 2026, Relmada Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “Charter Amendment”). The Charter Amendment was approved by the Company’s stockholders at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). held on May 27, 2026. The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.1.

Item 5.07. Submission of Matters to a Vote of Security Holders. On May 27, 2026, the Company held its Annual Meeting. Of the 104,888,223 shares of the Company’s common stock outstanding and eligible to vote at the Annual Meeting, 66,571,711 shares, or approximately 63.47% of the eligible common stock, were present either in person or by proxy and voted. The final results of the matters voted on at the Annual Meeting are provided below. Proposal 1: Election of Directors. Stockholders elected the following nominees as directors to hold office until the 2029 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified or until his earlier resignation or removal. Nominee For Withheld Broker Non-Votes ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Charles J. Casamento (Class II, 36 month term) 33,859,106 20,888,478 11,824,127 Sergio Traversa (Class II, 36 month term) 54,124,764 622,820 11,824,127 The continuing Class I Director is Fabiana Fedeli. The continuing Class III Directors are Paul Kelly and John Glasspool. Proposal 2: Ratification of Appointment of Independent Auditors. Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Withheld Broker Non-Votes ─────────────────────────────────────────────────────────────── 66,097,327 104,854 369,530 - Proposal 3: Approval of an Amendment to the 2021 Plan. Stockholders approved the proposed amendment to the Company’s 2021 Equity Incentive Plan, as amended (the “2021 Plan”), to increase the number of shares of the Company’s common stock available for issuance pursuant to awards under the 2021 Plan by 3,000,000 to an aggregate of 18,052,942 (including awards previously granted). The 2021 Plan is described in more detail in the Company’s 2026 Proxy Statement, which was filed with the Securities and Exchange Commission on April 17, 2026. For Against Withheld Broker Non-Votes ────────────────────────────────────────────────────────────────── 36,480,855 18,181,681 85,048 11,824,127 Proposal 4: Approval of the Charter Amendment Stockholders approved the proposed amendment to the Company’s Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 150,000,000 to 200,000,000. The Charter Amendment is described in more detail in the Company’s 2026 Proxy Statement, which was filed with the Securities and Exchange Commission on April 17, 2026 For Against Withheld Broker Non-Votes ───────────────────────────────────────────────────────────────── 65,072,921 1,170,378 328,412 -